Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Using sex steroids may increase lumbar spine BMD in male-to-female transgenders

04 Dec 2017
Doctors and therapists are said to be failing transgender patients due to their lack of knowledge and expertise in the area.

The use of masculinizing hormone therapy in female-to-male (FTM) transgenders is not likely to lead to significant changes in bone mineral density (BMD), but in male-to-female (MTF) individuals, the use of feminizing hormone therapy may result in an increase in BMD at the lumbar spine, a recent study has found.

“The impact of these BMD changes on patient-important outcomes such as fracture risk is uncertain,” according to researchers.

Several databases were comprehensively searched through 7 April 2015 for studies assessing bone health in transgender individuals receiving sex steroids. Studies were selected and appraised by pairs of reviewers. Finally, researchers pooled weighted mean differences and 95 percent confidence intervals (CIs) using a random effects model.

A total of 13 studies involving 639 transgender individuals (392 MTF and 247 FTM) were included in the analysis. The body of evidence was obtained mostly from observational studies with a moderate risk of bias.

Compared with baseline values before initiation of masculinizing hormone therapy, 12- and 24-month assessment data showed that FTM individuals had no statistically significant difference in the lumbar spine, femoral neck or total hip bone BMD.

On the other hand, MTF individuals had a statistically significant increase in lumbar spine BMD at 12 months (0.04 g/cm2; 95 percent CI, 0.03 to 0.06 g/cm2) and 24 months (0.06 g/cm2; 0.04 to 0.08 g/cm2) when compared with baseline values before they started using feminizing hormone therapy.

No events were reported at 12 months following the assessment of fracture rates in a single cohort of 53 MTF and 53 FTM individuals.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.